Ranbaxy Suspends API Shipments from Two Plants in India
PTSM: Pharmaceutical Technology Sourcing and Management
Daiichi Sankyo announced suspension of API shipments from Ranbaxy's Toansa and Dewas plants; issues apology to stakeholders.
Ranbaxy Laboratories has announced that it has temporarily suspended shipments of active pharmaceutical ingredients (APIs) produced at its Toansa and Dewas plants in India.
On Jan. 24, the company announced that API shipments from the Toansa plant to the United States were suspended. The company says it has now voluntarily suspended all API shipments from both the Toansa and Dewas plants in order to allow for further evaluation and inspection of manufacturing processes and quality control systems. The temporarily suspended shipments will be resumed once the processes and controls at these facilities are reconfirmed based on internal evaluations and inspections.
Ranbaxy has also announced that a Quality and Integrity Committee, established as a sub-committee of the Ranbaxy Corporate Board of Directors in order to improve corporate governance, has been in operation from early February 2014.
In a statement, parent company Daiichi Sankyo issued an apology to all its stakeholders “for the inconvenience caused by the further suspension of API shipments this time. As Ranbaxy is one of our most important affiliates in the Group, Daiichi Sankyo is committed to continuing to offer full support for Ranbaxy to improve quality standards,” the statement read.
Source: Daiichi Sankyo
